SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs

SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs

Abstract Perturbations of the circadian clock are linked to multiple diseases, including cancers. Pharmacological activation of REV-ERB nuclear receptors, the core components of the circadian clock, has antitumor effects on various malignancies, while the impact of SR9009 on prostate cancer (PCa) re...

Full description

Bibliographic Details
Main Authors: Hang Xu, Jiapeng Zhang, Xiaonan Zheng, Ping Tan, Xingyu Xiong, Xianyanling Yi, Yang Yang, Yan Wang, Dazhou Liao, Hong Li, Qiang Wei, Jianzhong Ai, Lu Yang
Format: Article
Language:English
Published: Nature Publishing Group 2022-11-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05392-6

Internet

https://doi.org/10.1038/s41419-022-05392-6

Similar Items